Synta Pharmaceuticals Corp. (SNTA) Drops 10.76% on January 06

Equities Staff |

Synta Pharmaceuticals Corp. (SNTA) was one of the Russell 2000's biggest losers for Wednesday January 06 as the stock slid 10.76% to $0.30, a loss of $-0.0365 per share. Starting at an opening price of $0.35 a share, the stock traded between $0.30 and $0.36 over the course of the trading day. Volume was 1.3 million shares over 3,150 trades, against an average daily volume of 1.85 million shares and a total float of 137.79 million.

The losses send Synta Pharmaceuticals Corp. down to a market cap of $41.69 million. In the last year, Synta Pharmaceuticals Corp. has traded between $3.17 and $0.29, and its 50-day SMA is currently $0.45 and 200-day SMA is $1.75.

Synta Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients.

Synta Pharmaceuticals Corp. is based out of Lexington, MA and has some 110 employees. Its CEO is Chen Schor.

For a complete fundamental analysis analysis of Synta Pharmaceuticals Corp., check out’s Stock Valuation Analysis report for SNTA. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Kiwa Bio-Tech Products Group Corp

Kiwa Bio-Tech Products Group Corp develops, manufactures, distributes and markets, cost-effective and environmentally safe bio-technological products for agriculture in China.

Private Markets


Uber connects riders with safe, reliable, convenient transportation providers at a variety of price-points in cities around the world. Uber makes money from charging their drivers 20% of the fare…


Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…